Tuesday, February 08, 2011 3:51:12 PM
What company would want to own branded Copaxone if Teva and MNTA were joining forces to bring generic Copaxone to market? The answer is: nobody.
Of course, TEVA might ask themselves "Would the net benefit be in our favor were we to somehow distance ourselves from Copaxone ownership?" The way I've gathered TEVA conducts itself (like it's fighting a war, as I believe you said) I would think they've thought through a purchase scenario, with all its ramifications.
Hey, at this point, I just want the pps to go up!
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
